AzTrials
AzTrials

Absorption; Disorder, ProteinGen3NCT04615858

Genepro Generation 3 Protein Bioavailability Compared to Whey Protein

A study testing Genepro Generation 3 Protein and Whey Protein in people with Absorption; Disorder, Protein and Protein Malabsorption, run by Musclegen Research, Inc. at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective of Clinical Trial: To test, in a blinded study the bioavailability of Genepro Generation 3 (GEN3) Protein as compared to whey protein. This study is intended to show the equivalent value of Genepro Gen3 as compared to whey protein (1scoop (12g) Genepro Generation 3 (GEN3) compared to 30g serving of whey… Read more about this study

Who is it for?
Ages 25 to 80 yearsHealthy volunteers can take part
What is being tested?
Genepro Generation 3 Protein and Whey Protein
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
2 sitesUnited States
Study dates
1 Dec 2020to 1 Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Participants will be solicited to volunteer through WakeMed Bariatric Surgery Center (current patients)
  • All participants must have normal blood protein levels prior to the study
  • All participants must be six months post op (bariatric surgery)
  • All participants must avoid any other protein supplementation during the trial period
  • All participants are required to maintain a daily nutrition log
  • All participants must have no milk/dairy allergies
Show all 9Show fewer
  • Age Eligibility: 25 years to 80 years (Adult)
  • Sexes Eligibility for Study: ALL
  • Only Accepts Healthy Volunteers

Who cannot join

  • No candidates with prior digestive distress disorders (IBS, Crones, etc.)
  • Participants with any negative GI score, they will be excluded from the study
  • Participants with abnormal blood protein levels at the time of study
  • Unhealthy Volunteers
  • Volunteers with compromised immune systems
  • Volunteers younger than 25 years of age
  • Volunteers older than 80 years of age
  • Allergies to milk or lactose

Trial locations and contacts

2 sites in 1 country.

United States2 sites, 2 recruiting
  • WakeMed Bariatric Surgery Center

    Cary, North Carolina, 27511

    Lamonica Daniel

    Marina Maddaloni

    Recruiting
  • WakeMed

    Raleigh, North Carolina, 27610

    TBD TBD

    Not yet recruiting

Other trials in United States

About this study

Official title: Genepro Generation 3 Bioavailability Compared to Whey Protein (12g Genepro vs 30g Whey)

Objective of Clinical Trial: To test, in a blinded study the bioavailability of Genepro Generation 3 (GEN3) Protein as compared to whey protein. This study is intended to show the equivalent value of Genepro Gen3 as compared to whey protein (1scoop (12g) Genepro Generation 3 (GEN3) compared to 30g serving of whey protein). Total Serum Protein levels will be tested every other week to evaluate blood protein levels in each participant

Read the detailed description

Detailed Description:

Condition or Disease: Analysis, Event History. Absorption; Disorder, protein

Objective of Clinical Trial: To test, in a blinded study the bioavailability of Genepro Generation 3 (GEN3) Protein as compared to whey protein. This study is intended to show the equivalent value of Genepro Gen3 as compared to whey protein (1scoop (12g) Genepro Generation 3 (GEN3) compared to 30g serving of whey protein). Total Serum Protein levels will be tested every other week to evaluate blood protein levels in each participant.

Parameters: This study encompasses a 6-week program that follows 40 gastric bypass patients that have undergone weight loss surgery. We will establish a baseline blood analysis prior to the start of the study and subsequently we will take bi-weekly blood work to chart and register the findings (weeks 2, 4 and 6). For this study we will only be doing the bi-weekly analysis on blood protein levels by utilizing Spectrophotometry with total serum protein. The target blood protein range is 6.1-8.7 g/dL this test is administered without fasting.

Participants: 40 Post Op Gastric Bypass patients. 20 men, 20 women. All participants were between the ages of 25-80 years of age. All participants have been post operation from their weight loss surgery for a minimum of 6 months prior to the start of the study and no longer than 8 months at the start of the study. Participants will be randomly selected, blindly, by the study sponsor. The selection will utilize participants files with names and ethnicity removed. Selection will be randomized into Group A and Group B. One group will be assigned Genepro while the other group will be assigned a leading whey protein powder. Participants will be assigned a Identification Code/Number for the duration of the study. Results will be posted using this identification number as well as stating the age and gender of the participant. Participant names will be held in confidence. Participants must maintain a daily log that will be shared with study investigators. This log will contain daily lists of food and beverage consumed as well as personal thoughts on taste and ease of use of protein supplements as well as a daily synopsis of overall general emotional and physical feelings.

Participant Compensation: Three (3) thirty serving units of Genepro Generation 3 at the conclusion of the study.

Gathering Results: 40 subjects will receive Genepro Generation 3 protein (12g serving) for one week prior to the study as well as all 6 weeks of the study. In conjunction the other group of 20 subjects will receive 30g whey protein for one week prior to the study as well as all 6 weeks of the study. Bi-Weekly blood analysis will determine blood protein levels. Blood draws are to be conducted at a WakeMed facility (Cary, NC or Raleigh, NC - determined by the proximity to the patient for their convenience). Results will be submitted for review and entry from WakeMed to the sponsor oversight POC every 2 weeks. To ensure proper transfer of data, WakeMed will keep and store all lab reports/results for a minimum of 2 years after the conclusion of the study. Soft copies will be inserted into a virtual storage center to be maintained and accessible by both, the sponsor as well as the medical partners.

Diet: Diet guidelines limit the calories you consume while providing you with balanced meals to help prevent nutritional deficiencies and preserve your muscle tissue. Each patient tolerates suggested foods differently. Daily calories should be between 600 to 700 for the duration of this study. Each subject is to follow a diet low in calories, fats and sweets. The goal for each subject is to consume a minimum of 65 to 75 grams of protein a day. High protein foods include eggs, meats, fish, seafood, tuna, poultry, tofu, milk, soy, cottage cheese, and yogurt. 30g of each daily intake of protein will be provided by a powdered protein supplement. 20 subjects will utilize a 30g serving of whey protein for 1 week prior to the study as well as 6 weeks of the study. The other group of 20 subjects will use a single serving (12g) of Genepro Gen3 Protein over the same duration.

Subject were given the following eating guidelines:

  • Eat slowly and chew small bites of food thoroughly.
  • Avoid rice, bread, raw vegetables, fresh fruits, and meats that are not easily chewed such as pork and steak. Ground meats are usually better tolerated.
  • With soft and solid foods, take only three bites at one sitting, then wait a minimum of 20 minutes before eating more.
  • Eat balanced meals with small portions.
  • Avoid the use of drinking straws and carbonated beverages, chewing gum and ice because they can introduce too much air into your pouch and cause discomfort.
  • Avoid sugar, sugar-containing foods and beverages, concentrated sweets, and fruit juices Alcoholic beverages will have a more profound effect and should be avoided or consumed with caution.

Storage and Distribution of Protein Powder: WakeMed Clinical Oversight Manager and Principal Investigator, Marina Maddaloni, will be provided with a lockable storage container to be positioned in her personal office. WakeMed will be provided white and black containers. One color will house either Genepro or regular Whey protein. WakeMed will not have knowledge of which color container holds which protein powder to ensure that the distribution to participants is totally blinded. Participants will be given enough protein supplementation, either regular whey or Genepro Generation 3 protein, to last the duration of the study.

Peer Reviewer 1: Dr. Brian M. Parks Peer Reviewer 2: Zac Cain Non-Peer Review: Dr. Jon Bruce

Being tested
Genepro Generation 3 Protein, Whey Protein
Keywords
protein, absorption

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Genepro Generation 3 ProteinDietary supplement

    Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.

  • Whey ProteinDietary supplement

    Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.

Study groups in NCT04615858
Study groupRoleWhat they receive
Genepro Generation 3Active comparator1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
Receives: Dietary Supplement: Genepro Generation 3 Protein
Whey ProteinActive comparator1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
Receives: Dietary Supplement: Whey Protein

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood Protein Levels

    Each participant in each group will have blood protein levels checked via blood draw at a WakeMed facility (based on participants geographic location). The target blood protein range is 6.1-8.7 g/dL this test is administered without fasting.

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Nov 2020
  2. Study start1 Dec 2020 (estimated)
  3. Primary completion26 Jan 2021 (estimated)
  4. Study completion1 Feb 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04615858
Sponsor's protocol ID
Genepro Gen3
Other IDs
033300391, Patent Pending
Acronym
Gen3
Status last verified
Nov 2020
First submitted
22 Oct 2020
Last updated
10 Nov 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Genepro Generation 3 Protein and Whey Protein in people with Absorption; Disorder, Protein and Protein Malabsorption, run by Musclegen Research, Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Brian M Parks, PHD (9196109893, bparks@geneproprotein.net), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood Protein Levels (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in